Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin最新文献

{"title":"Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.","authors":"Shelly Bolotin,&nbsp;Vanessa Tran,&nbsp;Shelley L Deeks,&nbsp;Adriana Peci,&nbsp;Kevin A Brown,&nbsp;Sarah A Buchan,&nbsp;Katherene Ogbulafor,&nbsp;Tubani Ramoutar,&nbsp;Michelle Nguyen,&nbsp;Rakesh Thakkar,&nbsp;Reynato DelaCruz,&nbsp;Reem Mustfa,&nbsp;Jocelyn Maregmen,&nbsp;Orville Woods,&nbsp;Ted Krasna,&nbsp;Kirby Cronin,&nbsp;Selma Osman,&nbsp;Eugene Joh,&nbsp;Vanessa G Allen","doi":"10.2807/1560-7917.ES.2021.26.50.2001559","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2021.26.50.2001559","url":null,"abstract":"<p><p>BackgroundSerosurveys for SARS-CoV-2 aim to estimate the proportion of the population that has been infected.AimThis observational study assesses the seroprevalence of SARS-CoV-2 antibodies in Ontario, Canada during the first pandemic wave.MethodsUsing an orthogonal approach, we tested 8,902 residual specimens from the Public Health Ontario laboratory over three time periods during March-June 2020 and stratified results by age group, sex and region. We adjusted for antibody test sensitivity/specificity and compared with reported PCR-confirmed COVID-19 cases.ResultsAdjusted seroprevalence was 0.5% (95% confidence interval (CI): 0.1-1.5) from 27 March-30 April, 1.5% (95% CI: 0.7-2.2) from 26-31 May, and 1.1% (95% CI: 0.8-1.3) from 5-30 June 2020. Adjusted estimates were highest in individuals aged ≥ 60 years in March-April (1.3%; 95% CI: 0.2-4.6), in those aged 20-59 years in May (2.1%; 95% CI: 0.8-3.4) and in those aged ≥ 60 years in June (1.6%; 95% CI: 1.1-2.1). Regional seroprevalence varied, and was highest for Toronto in March-April (0.9%; 95% CI: 0.1-3.1), for Toronto in May (3.2%; 95% CI: 1.0-5.3) and for Toronto (1.5%; 95% CI: 0.9-2.1) and Central East in June (1.5%; 95% CI: 1.0-2.0). We estimate that COVID-19 cases detected by PCR in Ontario underestimated SARS-CoV-2 infections by a factor of 4.9.ConclusionsOur results indicate low population seroprevalence in Ontario, suggesting that public health measures were effective at limiting the spread of SARS-CoV-2 during the first pandemic wave.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39593932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 trends and severity among symptomatic children aged 0-17 years in 10 European Union countries, 3 August 2020 to 3 October 2021.","authors":"Nick Bundle,&nbsp;Nishi Dave,&nbsp;Anastasia Pharris,&nbsp;Gianfranco Spiteri,&nbsp;Charlotte Deogan,&nbsp;Jonathan E Suk","doi":"10.2807/1560-7917.ES.2021.26.50.2101098","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101098","url":null,"abstract":"<p><p>We estimated risks of severe outcomes in 820,404 symptomatic paediatric COVID-19 cases reported by 10 European Union countries between August 2020 and October 2021. Case and hospitalisation rates rose as transmission increased but severe outcomes were rare: 9,611 (1.2%) were hospitalised, 640 (0.08%) required intensive care and 84 (0.01%) died. Despite increased individual risk (adjusted odds ratio hospitalisation: 7.3; 95% confidence interval: 3.3-16.2; intensive care: 8.7; 6.2-12.3) in cases with comorbidities, most (83.7%) hospitalised children had no comorbidity.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39593931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 - is the precautionary principle applicable?","authors":"Lucas Wiessing,&nbsp;Eleni Kalamara,&nbsp;Jack Stone,&nbsp;Peyman Altan,&nbsp;Luk Van Baelen,&nbsp;Anastasios Fotiou,&nbsp;D'Jamila Garcia,&nbsp;Joao Goulao,&nbsp;Bruno Guarita,&nbsp;Vivian Hope,&nbsp;Marie Jauffret-Roustide,&nbsp;Lina Jurgelaitienė,&nbsp;Martin Kåberg,&nbsp;Adeeba Kamarulzaman,&nbsp;Liis Lemsalu,&nbsp;Anda Kivite-Urtane,&nbsp;Branko Kolarić,&nbsp;Linda Montanari,&nbsp;Magdalena Rosińska,&nbsp;Lavinius Sava,&nbsp;Ilonka Horváth,&nbsp;Thomas Seyler,&nbsp;Vana Sypsa,&nbsp;Anna Tarján,&nbsp;Ioanna Yiasemi,&nbsp;Ruth Zimmermann,&nbsp;Marica Ferri,&nbsp;Kate Dolan,&nbsp;Anneli Uusküla,&nbsp;Peter Vickerman","doi":"10.2807/1560-7917.ES.2021.26.49.2002093","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2021.26.49.2002093","url":null,"abstract":"<p><p>BackgroundPeople who inject drugs (PWID) are frequently incarcerated, which is associated with multiple negative health outcomes.AimWe aimed to estimate the associations between a history of incarceration and prevalence of HIV and HCV infection among PWID in Europe.MethodsAggregate data from PWID recruited in drug services (excluding prison services) or elsewhere in the community were reported by 17 of 30 countries (16 per virus) collaborating in a European drug monitoring system (2006-2020; n = 52,368 HIV+/-; n = 47,268 HCV+/-). Country-specific odds ratios (OR) and prevalence ratios (PR) were calculated from country totals of HIV and HCV antibody status and self-reported life-time incarceration history, and pooled using meta-analyses. Country-specific and overall population attributable risk (PAR) were estimated using pooled PR.ResultsUnivariable HIV OR ranged between 0.73 and 6.37 (median: 2.1; pooled OR: 1.92; 95% CI: 1.52-2.42). Pooled PR was 1.66 (95% CI 1.38-1.98), giving a PAR of 25.8% (95% CI 16.7-34.0). Univariable anti-HCV OR ranged between 1.06 and 5.04 (median: 2.70; pooled OR: 2.51; 95% CI: 2.17-2.91). Pooled PR was 1.42 (95% CI: 1.28-1.58) and PAR 16.7% (95% CI: 11.8-21.7). Subgroup analyses showed differences in the OR for HCV by geographical region, with lower estimates in southern Europe.ConclusionIn univariable analysis, a history of incarceration was associated with positive HIV and HCV serostatus among PWID in Europe. Applying the precautionary principle would suggest finding alternatives to incarceration of PWID and strengthening health and social services in prison and after release ('throughcare').</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39710571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moral dilemma(s) in human papillomavirus vaccination - revisiting the role of the herd effect.","authors":"Matti Lehtinen,&nbsp;Ville N Pimenoff","doi":"10.2807/1560-7917.ES.2021.26.50.2101154","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101154","url":null,"abstract":"In this Eurosurveillance issue, two articles by Colzani et al. [1] and Ortu et al. [2], raise the question of who should be prioritised in vaccination policy when there is a temporary global shortage of vaccines. These articles on human papillomavirus (HPV) are a reminder that discussions pertaining to vaccination policies are not confined to coronavirus disease (COVID-19). Nonetheless, lessons learnt from the establishment of HPV vaccination are generalisable and valuable for the implementation and monitoring of most vaccination programmes, including those against COVID-19, worldwide.","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39593933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing risk of breakthrough COVID-19 in outbreaks with high attack rates in European long-term care facilities, July to October 2021.","authors":"Carl Suetens,&nbsp;Pete Kinross,&nbsp;Pilar Gallego Berciano,&nbsp;Virginia Arroyo Nebreda,&nbsp;Eline Hassan,&nbsp;Clémentine Calba,&nbsp;Eugenia Fernandes,&nbsp;Andre Peralta-Santos,&nbsp;Pedro Casaca,&nbsp;Nathalie Shodu,&nbsp;Sara Dequeker,&nbsp;Flora Kontopidou,&nbsp;Lamprini Pappa,&nbsp;Oliver Kacelnik,&nbsp;Anita Wang Børseth,&nbsp;Lois O'Connor,&nbsp;Patricia Garvey,&nbsp;Rasa Liausedienė,&nbsp;Rolanda Valintelienė,&nbsp;Corinna Ernst,&nbsp;Joël Mossong,&nbsp;Mária Štefkovičová,&nbsp;Zuzana Prostináková,&nbsp;Ann Caroline Danielsen,&nbsp;Aikaterini Mougkou,&nbsp;Favelle Lamb,&nbsp;Orlando Cenciarelli,&nbsp;Dominique L Monnet,&nbsp;Diamantis Plachouras","doi":"10.2807/1560-7917.ES.2021.26.49.2101070","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2021.26.49.2101070","url":null,"abstract":"<p><p>We collected data from 10 EU/EEA countries on 240 COVID-19 outbreaks occurring from July-October 2021 in long-term care facilities with high vaccination coverage. Among 17,268 residents, 3,832 (22.2%) COVID-19 cases were reported. Median attack rate was 18.9% (country range: 2.8-52.4%), 17.4% of cases were hospitalised, 10.2% died. In fully vaccinated residents, adjusted relative risk for COVID-19 increased with outbreak attack rate. Findings highlight the importance of early outbreak detection and rapid containment through effective infection prevention and control measures.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39571982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating the transmission advantage of the D614G mutant strain of SARS-CoV-2, December 2019 to June 2020.","authors":"Kathy Leung,&nbsp;Yao Pei,&nbsp;Gabriel M Leung,&nbsp;Tommy Ty Lam,&nbsp;Joseph T Wu","doi":"10.2807/1560-7917.ES.2021.26.49.2002005","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2021.26.49.2002005","url":null,"abstract":"<p><p>IntroductionThe SARS-CoV-2 lineages carrying the amino acid change D614G have become the dominant variants in the global COVID-19 pandemic. By June 2021, all the emerging variants of concern carried the D614G mutation. The rapid spread of the G614 mutant suggests that it may have a transmission advantage over the D614 wildtype.AimOur objective was to estimate the transmission advantage of D614G by integrating phylogenetic and epidemiological analysis.MethodsWe assume that the mutation D614G was the only site of interest which characterised the two cocirculating virus strains by June 2020, but their differential transmissibility might be attributable to a combination of D614G and other mutations. We define the fitness of G614 as the ratio of the basic reproduction number of the strain with G614 to the strain with D614 and applied an epidemiological framework for fitness inference to analyse SARS-CoV-2 surveillance and sequence data.ResultsUsing this framework, we estimated that the G614 mutant is 31% (95% credible interval: 28-34) more transmissible than the D614 wildtype. Therefore, interventions that were previously effective in containing or mitigating the D614 wildtype (e.g. in China, Vietnam and Thailand) may be less effective against the G614 mutant.ConclusionOur framework can be readily integrated into current SARS-CoV-2 surveillance to monitor the emergence and fitness of mutant strains such that pandemic surveillance, disease control and development of treatment and vaccines can be adjusted dynamically.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39571981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021.","authors":"Ria Lassaunière,&nbsp;Charlotta Polacek,&nbsp;Jannik Fonager,&nbsp;Marc Bennedbæk,&nbsp;Lasse Boding,&nbsp;Morten Rasmussen,&nbsp;Anders Fomsgaard","doi":"10.2807/1560-7917.ES.2021.26.49.2101059","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2021.26.49.2101059","url":null,"abstract":"<p><p>Several factors may account for the recent increased spread of the SARS-CoV-2 Delta sub-lineage AY.4.2 in the United Kingdom, Romania, Poland, and Denmark. We evaluated the sensitivity of AY.4.2 to neutralisation by sera from 30 Comirnaty (BNT162b2 mRNA) vaccine recipients in Denmark in November 2021. AY.4.2 neutralisation was comparable to other circulating Delta lineages or sub-lineages. Conversely, the less prevalent B.1.617.2 with E484K showed a significant more than 4-fold reduction in neutralisation that warrants surveillance of strains with the acquired E484K mutation.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39710572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low vaccination coverage for human papillomavirus disease among young men who have sex with men, France, 2019.","authors":"Giuseppina Ortu,&nbsp;Anne-Sophie Barret,&nbsp;Kostas Danis,&nbsp;Lucie Duchesne,&nbsp;Daniel Levy-Bruhl,&nbsp;Annie Velter","doi":"10.2807/1560-7917.ES.2021.26.50.2001965","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2021.26.50.2001965","url":null,"abstract":"<p><p>BackgroundIn France, human papillomavirus (HPV) vaccination has been recommended in 2016 for men who have sex with men (MSM) up to age 26 years.AimWe aimed to estimate HPV vaccine coverage in 18-28 year-old MSM and identify uptake determinants.MethodsWe collected data on socio-demographic characteristics, sexual behaviour, sexually transmitted diseases (STI) screening and vaccination uptake using a voluntary cross-sectional online survey conducted in 2019 targeting MSM. We calculated coverage of at least one dose of HPV vaccine and prevalence ratios (PR) of determinants with 95% confidence intervals (CI) using Poisson regression.ResultsOf 9,469 respondents (age range: 18-28 years), 15% (95% CI: 14-16) reported being vaccinated for HPV. Coverage was significantly higher among MSM < 24 years (PR: 1.25; 95% CI: 1.13-1.39), with education level below university degree (PR: 1.12; 95% CI: 1.08-1.32), living in rural areas (PR: 1.21; 95% CI: 1.08-1.36), attending sex parties (PR: 1.12; 95% CI: 1.03-1.33), using HIV-related biomedical prevention methods (PR: 1.31; 95% CI: 1.12-1.54), with STI diagnosis (PR: 1.22; 95% CI: 1.08-1.38) and with hepatitis A or B vaccination (PR: 4.56; 95% CI: 3.63-5.81 vs PR: 3.35; 95% CI: 2.53-4.44).ConclusionsThe HPV vaccination uptake among MSM in France was not satisfactory. It was higher among MSM benefitting from other vaccinations and biomedical preventive methods against HIV, suggesting a synergistic effect of the national preventive sexual health recommendations for MSM. Further efforts to improve HPV vaccination coverage targeting MSM are warranted.</p>","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39608991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021.","authors":"Laura Espenhain,&nbsp;Tjede Funk,&nbsp;Maria Overvad,&nbsp;Sofie Marie Edslev,&nbsp;Jannik Fonager,&nbsp;Anna Cäcilia Ingham,&nbsp;Morten Rasmussen,&nbsp;Sarah Leth Madsen,&nbsp;Caroline Hjorth Espersen,&nbsp;Raphael N Sieber,&nbsp;Marc Stegger,&nbsp;Vithiagaran Gunalan,&nbsp;Bartlomiej Wilkowski,&nbsp;Nicolai Balle Larsen,&nbsp;Rebecca Legarth,&nbsp;Arieh Sierra Cohen,&nbsp;Finn Nielsen,&nbsp;Janni Uyen Hoa Lam,&nbsp;Kjetil Erdogan Lavik,&nbsp;Marianne Karakis,&nbsp;Katja Spiess,&nbsp;Ellinor Marving,&nbsp;Christian Nielsen,&nbsp;Christina Wiid Svarrer,&nbsp;Jonas Bybjerg-Grauholm,&nbsp;Stefan Schytte Olsen,&nbsp;Anders Jensen,&nbsp;Tyra Grove Krause,&nbsp;Luise Müller","doi":"10.2807/1560-7917.ES.2021.26.50.2101146","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101146","url":null,"abstract":"By 9 December 2021, 785 SARS-CoV-2 Omicron variant cases have been identified in Denmark. Most cases were fully (76%) or booster-vaccinated (7.1%); 34 (4.3%) had a previous SARS-CoV-2 infection. The majority of cases with available information reported symptoms (509/666; 76%) and most were infected in Denmark (588/644; 91%). One in five cases cannot be linked to previous cases, indicating widespread community transmission. Nine cases have been hospitalised, one required intensive care and no deaths have been registered.","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39608993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: Increase of influenza vaccination coverage rates during the COVID-19 pandemic and implications for the upcoming influenza season in northern hemisphere countries and Australia.","authors":"Marco Del Riccio,&nbsp;Bruno Lina,&nbsp;Saverio Caini,&nbsp;Lisa Staadegaard,&nbsp;Sytske Wiegersma,&nbsp;Jan Kynčl,&nbsp;Béhazine Combadière,&nbsp;Chandini Raina MacIntyre,&nbsp;John Paget","doi":"10.2807/1560-7917.ES.2021.26.50.2101143","DOIUrl":"https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101143","url":null,"abstract":"Marco Del Riccio1,2 , Bruno Lina3 , Saverio Caini1 , Lisa Staadegaard1 , Sytske Wiegersma1 , Jan Kynčl4 , Béhazine Combadière5 , Chandini Raina MacIntyre6 , John Paget1 1. Netherlands Institute for Health Services Research (Nivel), Utrecht, Netherlands 2. Postgraduate School in Hygiene and Preventive Medicine, University of Florence, Florence, Italy 3. VirPath Laboratory, University of Lyon, Lyon, France 4. Department of Infectious Diseases Epidemiology, National Institute of Public Health, Prague, Czech Republic 5. Inserm, Centre d’Immunologie et des Maladies Infectieuses, Sorbonne Université, France 6. Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":19.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39608992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}